China Health Technology Group Holding Company Limited (1069) has announced its unaudited interim results for the six months ended 31 December 2025. During the reporting period, revenue reached RMB34.39 million, compared to RMB31.11 million in the same period of 2024. Gross profit stood at RMB4.14 million, up from RMB2.78 million in the previous period. The profit for the period rose slightly to RMB5.25 million, compared to RMB4.98 million in the prior year.
The company’s key businesses include forestry management, ginseng plantation and trading, horny goat weed plantation, and health products trading. Forestry operations generated RMB7.07 million in revenue, primarily from timber log sales. The ginseng segment contributed RMB16.78 million, driven by both its self-grown and purchased inventory of ginseng. No revenue was recorded from the horny goat weed plantation during the period. The health products segment, involving the sale of ginseng gift boxes and other items, reported RMB10.55 million in revenue.
As of 31 December 2025, total assets were RMB201.32 million, while total liabilities were RMB144.43 million, leading to net assets of RMB56.89 million. Basic profit per share was 5.25 RMB cents compared to 6.30 RMB cents in the same period last year. No interim dividend was proposed.
Comments